Apabetalone
A bromodomain and extraterminal domain inhibitor.
General information
Apabetalone is a quinazoline drug investigated for the treatment of atherosclerosis, diabetes, and coronary artery disease (DrugBank).
Apabetalone on PubChem
Apabetalone on Wikipedia
Synonyms
RVX-208
CC1=CC(=CC(=C1OCCO)C)C2=NC3=C(C(=CC(=C3)OC)OC)C(=O)N2
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Small molecule |
in silico | 42.78 | Apr/30/2020 | |
|
Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro
Small molecule In vitro |
in vitro binding assays; Calu-3 cells; SARS-CoV-2 (strain BEI_USA-WA1/2020) | 6.08 | The drug downregulated ACE2 expression in various cell lines and inhibited SARS-CoV-2 infection in Calu-3 cells. It attenuated Spike protein binding in vitro. |
Apr/18/2021 |
AI-suggested references
| Link | Publication date |
|---|---|
|
BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection.
|
Mar/16/2021 |
Clinical trials
| ID | Title | Status | Phase | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04894266 | An Open-Label Study of Apabetalone in Covid Infection | Recruiting | Phase 2|Phase 3 | Jan/14/2022 | Sep/22/2022 |
|
|||||
